Devices, systems, and methods for tumor visualization and removal

Abstract

A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one ofprecancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.

Description

[0001] This application claims priority to Provisional Application Nos. 62 / 625,967, filed February 2, 2018, 62 / 625,983, filed February 3, 2018, and 62 / 793,843, filed January 17, 2019, The entire content of each application is incorporated herein by reference. technical field [0002] The present disclosure relates to devices, systems and methods for tumor visualization and resection. The disclosed devices, systems, and methods can also be used to stage tumors and evaluate surgical margins and specimens, such as tissue margins, resected tissue specimens, and tissue sections of resected tumors, and tissue / surgical beds from which tumors and / or tissue have been resected incisal margin. The disclosed devices, systems, and methods can also be used to identify one or more of residual cancer cells, precancerous cells, and satellite lesions, and to provide guidance for their resection and / or treatment. The disclosed devices can be used to obtain materials for diagnostic and planning...

AI Technical Summary

Problems solved by technology

The outcome of BCS depends on complete removal of the malignant tissue while preserving enough healthy breast tissue to ensure adequate breast reconstruction and may be less effective if too much breast tissue is removed

Visualizing tumor margins under standard white-light (WL) operating room conditions is challenging due to low tumor-to-normal tissue contrast, resulting in reoperation in approximately 23% of patients with early invasive breast cancer and 36% of patients with DCIS (ie, secondary surgery)

Images